SCCA Lymphoma Clinical Trials

SCCA Lymphoma Clinical Trials

SGN-35 for CD30-positive Malignancies/Previous SGN-35 study (UW09044)
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Status Conditions Phase Study ID
Closed Lymphoma Phase II UW09044

This is a multicenter, open-label study to evaluate the safety and efficacy of treatment with SGN-35 in patients who have previously participated in an SGN-35 study.

Ajay Gopal, MD
Seattle Cancer Care Alliance 800-804-8824  
Eligibility Criteria (must meet the following to participate in this study)
Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participated in a previous SGN-35 study.
  • CD30-positive hematologic malignancy.
  • At a minimum, experienced clinical benefit in the prior SGN-35 study.

Exclusion Criteria:

Withdrew consent to participate in any prior SGN-35 study.

Last Updated
September 14, 2012
See this trial at
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.